Anzeige
Mehr »
Donnerstag, 13.08.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
198 Leser
Artikel bewerten:
(1)

Black Book Research: Healthcare Machine Learning Hits Production Scale as Governance Falls Behind, Black Book's Fourth Annual Report Finds

U.S.-EU benchmark finds 78% of healthcare organizations operate AI/ML in sustained production, while only 19% maintain complete lifecycle controls

CHICAGO, IL / ACCESS Newswire / August 13, 2026 / Black Book Research today released its fourth annual healthcare machine learning study, The State of Healthcare Machine Learning 2026: U.S.-EU Adoption, Innovation, Assurance and 2027 Demand Outlook. The report tracks the transition from experimentation to sustained clinical, administrative and operational use across the United States and European Union.

Based on 230 senior healthcare ML leaders (130 in the United States and 100 across 12 EU member states) the study documents substantial domestic and international innovation while revealing a widening assurance gap. Seventy-eight percent of represented organizations have at least one AI or ML system in sustained production, but only 19% maintain complete controls for ownership, local validation, monitoring, change management, incident response, rollback and retirement.

"Healthcare machine learning has entered a more consequential phase, where deployment alone is no longer the measure of progress," said Doug Brown, founder of Black Book Research. "The organizations positioned to lead in 2027 will be those that can validate models locally, monitor calibration and subgroup performance, detect drift, govern version changes and demonstrate measurable net benefit in live workflows. Building that operational infrastructure will allow health systems to scale machine learning with greater precision, resilience and confidence."

Among the principal findings, 83% of respondents are evaluating or using healthcare large language model applications, 57% report production LLM use and 61% report observed or suspected shadow use of unapproved public tools. Sixty-three percent rank EHR, PACS, RIS, LIS or workflow integration among the leading reasons promising pilots fail to scale. In addition, 68% report at least one model that met its technical target while increasing workload, testing, false positives or utilization, and only 27% say realized benefits usually or always meet the original business case.

The two markets show different areas of progress. U.S. organizations lead in production LLM adoption, at 64% compared with 49% in the EU, and report faster pilot-to-production conversion. EU organizations lead in formal governance, local validation, model documentation, patient disclosure and role-specific AI literacy, reported by 71% of EU respondents versus 48% in the United States.

Governance structures are forming faster than operating controls. Although 72% report a formal AI governance body, only 29% can produce a complete production-model inventory within 48 hours. Just 32% revalidate every major model-version change, and only 22% can retain a previous vendor model when an update underperforms, exposing gaps in version governance, rollback readiness and retirement planning.

Post-deployment monitoring remains concentrated on technical performance rather than real-world impact. While 76% monitor technical discrimination or accuracy, only 39% track calibration, 36% subgroup and equity performance, 32% clinical outcomes and 28% workflow burden. Only 6% of EU respondent organizations reached "assured enterprise scale," while 35% were classified as carrying high governance debt or operating with uncontrolled adoption.

Looking to 2027, 75% expect AI and ML budgets to increase. Monitoring and drift detection, workflow integration, LLM governance, data provenance and outcome measurement all rank ahead of acquiring additional models. Black Book's 18-KPI Clinical ML Operational Integrity Index scored the combined market at 58.9 out of 100, placing healthcare ML in the "managed but pilot-heavy" maturity band.

Both European and US Healthcare ML Industry stakeholders can download the report through Q3 at:

https://blackbookmarketresearch.com/the-state-of-healthcare-machine-learning-2026-2027-outlook

About Black Book Research

Black Book Research is an independent healthcare market research and competitive intelligence firm providing data-driven evaluations of healthcare technology, services and market performance through direct stakeholder feedback and structured methodologies without vendor sponsorship or pay-to-play influence. Black Book now covers 110 countries' healthcare IT sectors.

Media Contact
research@blackbookmarketresearch.com
1-800-863-7590

SOURCE: Black Book Research



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/healthcare-machine-learning-hits-production-scale-as-governance-falls-1206474

© 2026 ACCESS Newswire
Achtung, Korrektur!
Die Börsen laufen heiß. Trotz geopolitischer Krisen und steigender Zinsen klettern viele Indizes weiter Richtung Allzeithoch. Doch unter der Oberfläche zeigen sich erste Risse: Der Abverkauf bei Halbleiter-, KI- und Space-Aktien macht deutlich, wie schnell sich die Stimmung drehen kann.

Besonders gefährlich ist die aktuelle Gemengelage aus schwacher Saisonalität, dünner Liquidität in den Sommermonaten und historisch hohen Bewertungen. Selbst vermeintlich sichere Blue Chips sind inzwischen teuer bewertet und damit anfällig für Korrekturen. Gleichzeitig liefern technische Indikatoren erste Warnsignale. So werden viele Rekordstände nicht mehr bestätigt.

Für Anleger steigen die Risiken spürbar. Wer jetzt nicht genauer hinschaut, läuft Gefahr, auf dem falschen Fuß erwischt zu werden.

In unserem aktuellen Spezialreport zeigen wir fünf Aktien, bei denen die Abwärtsrisiken besonders hoch sind – und wo sich Gewinnmitnahmen oder sogar Short-Strategien anbieten könnten.

Jetzt den kostenlosen Report sichern – bevor die Korrektur Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.